Drug intelligence / Profile preview

Influenza A (H5N8) Monovalent Vaccine

Development stage: Phase 1
Lead developer: CSL Seqirus
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

A pandemic influenza vaccine designed to protect against the H5N8 strain of avian influenza virus. This vaccine is being developed as part of pandemic preparedness efforts to address highly pathogenic avian influenza (HPAI) A(H5) viruses that have caused outbreaks in wild birds, poultry, and occasionally humans. The vaccine is based on the A/Astrakhan/3212/2020 (clade 2.3.4.4b) strain.

Other names: H5N8 A/Astrakhan vaccineInfluenza A(H5N8) A/Astrakhan/3212/2020 vaccine

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on Influenza A (H5N8) Monovalent Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A (H5N8) Monovalent Vaccine.

Explore the full profile